Compare Mesoblast Limited (MESO) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Select Medical Holdings Corporation — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Mesoblast Limited and Select Medical Holdings Corporation are close in size by market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SEM | |
|---|---|---|
Market Cap | $2.17B | $2.05B |
Sector | Technology | Health |
52-Week High | $20.96 | $16.66 |
52-Week Low | $12.88 | $11.77 |
Enterprise Value | $2.17B | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported 2025 revenue of $5.45 billion with a net income margin of 2.42%, while valuation ratios like a P/E of 15.43 and P/S of 0.36 appear reasonable. Recent earnings show two misses in the last three quarters against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the $16.50 deal price. Risks include ongoing shareholder litigation alleging fiduciary breaches by the board regarding the buyout fairness. Analyst sentiment is neutral with a Hold-heavy consensus, while the stock's future price action will largely hinge on legal outcomes surrounding the acquisition terms rather than operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
